WIXOM, Mich., Aug. 3, 2018 /PRNewswire/ -- Rockwell Medical,
Inc. (NASDAQ: RMTI) (the "Company") announced today that it will hold a conference call to provide commentary on the business on
Tuesday, August 14, 2018, at 5:00 pm Eastern Time. A copy of the
earnings release for the second quarter 2018 will be made available on August 14, 2018 after the
markets close.
This second quarter 2018 business update conference call is also being webcast and can be accessed at the Rockwell Medical
Investor Relations web page. You can join this call on:
Date:
|
Tuesday, August 14
|
Time:
|
5:00 pm ET
|
Dial in number:
|
(866) 610-1072
|
International dial in:
|
(973) 935-2840
|
Passcode:
|
3884015
|
Webcast:
|
http://ir.rockwellmed.com
|
The Company also announced that on or before August 9, 2018, Rockwell Medical intends to file a
Form 12b-25 with the Securities and Exchange Commission providing the Company an automatic 5-day extension to file its Form 10-Q
for the quarter ended June 30, 2018. As previously disclosed, the Company engaged Marcum LLP as the
Company's new independent registered public accounting firm on July 26, 2018. The Company is
working diligently and plans to use the extension to complete its work and file its second quarter Form 10-Q within the 5-day
extension period provided by Rule 12b-25.
About Rockwell Medical, Inc.
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney
disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin
in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the
delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and
maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in
the U.S. dialysis market and other major markets globally.
Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol
(active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has
been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an
improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis
market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to
dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products
are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream.
Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of
dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and
improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for
indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Forward-Looking Statement
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, Rockwell's intention to bring to market Triferic and Calcitriol. Words such as
"may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential,"
"predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date
of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various
risks and uncertainties (including without limitation those set forth in Rockwell's SEC filings), many of which are beyond our
control and subject to change Actual results could be materially different. Risks and uncertainties include: the ongoing
litigation with Rockwell's former Chief Executive Officer, Chief Financial Officer and certain current and former directors; the
timing for the appointment of a successor Chief Executive Officer, Chief Financial Officer; Rockwell's ability to maintain
compliance with SEC and NASDAQ rules and requests; and whether Rockwell can successfully execute on its business strategy.
Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future
events or otherwise, except as required by law.
Contacts
Dan Katcher / Kelly Sullivan / Arielle Rothstein
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
View original content:http://www.prnewswire.com/news-releases/rockwell-medical-schedules-second-quarter-2018-business-update-conference-call-and-provides-timeline-of-form-10-q-filing-300691695.html
SOURCE Rockwell Medical, Inc.